The biology of Alzheimer's disease

Mechanisms of Ageing and Development

Volumn 91, Issue 2, 1996, Pages 95-114

  Edelberg, Helen K ^a   Wei, Jeanne Y ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; DNA damage; Excitotoxicity; Genetic; Inflammatory; Oxidative; Review

Indexed keywords

EXCITOTOXIN; OXYGEN RADICAL;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; DISEASE COURSE; DNA DAMAGE; HUMAN; NEUROFIBRILLARY TANGLE; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; VASCULAR AMYLOIDOSIS;

EID: 0030601847     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/0047-6374(96)01778-2     Document Type: Article

References (81)

1. [1] T. Saitoh, Y. Xia, X. Chen et al., The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol., 37 (1995) 110-112.
2. [2] S.E. Gandy, Other degenerative disorders of the nervous system. In W.R. Hazzard and E.L. Bierman (eds.), Principles of Geriatric Medicine and Gerontology, 3rd edn, McGraw Hill, New York, USA, 1995, pp. 1064.
3. [3] C.F. Lippa, T.W. Smith, L. Nee et al., Familial Alzheimer's disease and cortical Lewy bodies: is there a genetic susceptibility factor? Dementia, 6 (1995) 191-194.
4. [4] S.S. Mirra, M.N. Hart, and R.D. Terry, Making the diagnosis of Alzheimer's disease: a primer for practicing pathologists. Arch. Pathol. Lab. Med., 117 (1993) 132-144.
5. [5] B.L. Strehler, New theory of hippocampal function: Associated rehearsal of multiplexed coded symbols. Synapse, 3 (1989) 182-192.
6. [6] J. Naslund, A. Schierhorn, U. Hellman et al., Relative abundance of Alzheimer β-amyloid peptide variants in Alzheimer's disease and normal aging. Proc. Natl. Acad. Sci. USA, 91 (1994) 8378-8382.
7. [7] R Mayeux and P.W. Schofield, Alzheimer's disease. In WR Hazzard and EL Bierman (eds.), Principles of Geriatric Medicine and Gerontology, 3rd edn, New York, USA, 1995, pp. 1035-1050.
8. [8] M.F. Beal, Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol., 38 (1995) 357-366.
9. [9] A. Goate, M.C. Chartier-Harlin, M. Mullan et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349 (1991) 704-706.
10. [10] M.C. Chartier-Harlin, F. Crawford, H. Houlden et al., Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature, 353 (1991) 844-846.
11. [11] R. Sherrington, E.I. Rogaev, Liang et al., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 375 (1995) 754-760.
12. [12] E. Levy-Lahad et al., Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, 269 (1995) 973-977.
13. [13] C. Van Broeckhoven, Presenilins and Alzheimer's disease. Nature Genetics, 11 (1995) 230-232.
14. [14] M.E. Boerrigter, J.Y. Wei and J. Vijg, DNA repair and Alzheimer's disease. J. Gerontol., 47 (1992) B177-B184.
15. [15] Q.X. Li et al., Membrane-associated forms of the β A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood, 84 (1994) 133-142.
16. [16] I. Kushner, The acute phase response: from Hippocrates to cytokine biology. Eur. Cytokine Network, 2 (1991) 75-80.
17. [17] J. Trejo et al., A direct role for protein kinase C and the transcription factor Jun/AP-1 in the regulation of the Alzheimer's β-amyloid precursor protein gene. J. Biol. Chem., 269 (1994) 21 682-21 690.
18. [18] P.S. Aisen and K.L. Davis, Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiatry, 151 (1994) 1105-1113.
19. [19] D. Patterson et al., Mapping of the gene encoding the β-amyloid precursor protein and its relationship to the Down syndrome region of chromosome 21. Proc. Natl. Acad. Sci., 85 (1988) 8266-8270.
20. [20] M.P. Mattson, Untangling the pathophysiochemistry of β-amyloid. Nat. Structural Biol., 2 (1995) 926-928.
21. [21] R.E. Tanzi et al., Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature, 331 (1988) 528-532.
22. [22] T. Saitoh et al., Secreted form of amyloid β precursor protein is involved in the growth regulation of fibroblasts. Cell, 58 (1989) 615-622.
23. [23] S.L. Wagner et al., Decreased levels of soluble amyloid β-protein precursor are associated with Alzheimer's disease in concordant and discordant monozygous twin pairs. Ann. Neurol., 36 (1994) 215-220.
24. [24] M. Farlow, Low cerebrospinal-fluid β-protein precursor in hereditary Alzheimer's disease. Lancet, 340 (1992) 453-454.
25. [25] B.A. Yankner, L.K. Duffy, and D.A. Kirschner, Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 250 (1990) 279-282.
26. [26] D.A. Sanan et al., Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils: isoform ApoE4 associates more efficiently than ApoE3. J. Clin. Invest., 94 (1994) 860-869.
27. [27] P.T. Lansbury et al., Structural model for the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat. Structural Biol., 2 (1995) 990-998.
28. [28] H. Jiang et al., β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol., 152 (1994) 5050-5059.
29. [29] C. Haass and D. J. Selkoe, Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell, 75 (1993) 1039-1042.
30. [30] L. McConlogue et al., Differential effects of a rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's β-amyloid precursor protein. J Biol. Chem., 271 (1996) 1343-1348.
31. [31] E. Levy-Lahad et al., A familial Alzheimer's disease locus on chromosome 1. Science, 269 (1995) 970-973.
32. [32] D. Levitan and I. Greenwald, Facilitation of lin-12-mediated signalling by se1-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature, 377 (1995) 351-354.
33. [33] M. Jianyi et al., Amyloid-associated proteins α 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature, 372 (1994) 92-94.
34. [34] A.D. Roses, Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann. Neurol., 38 (1995) 6-14.
35. [35] J. Kawamata, S. Tanaka, K. Ueda, and J. Kimura, Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. J. Neurol. Neurosurg. Psychiatry, 57 (1994) 1414-1416.
36. [36] T. Wisniewski et al., Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol., 145 (1994) 1030-1035.
37. [37] C.R. Harrington et al., Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and lewy body types: significance for etiological theories of Alzheimer's disease. Am. J. Pathol., 145 (1994) 1472-1484.
38. [38] B.O. Osuntokin et al., Lack of association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. Ann. Neurol., 38 (1995) 463-465.
39. [39] G. Maestre et al., Apolipoprotein E and Alzheimer's disease: Ethnic variation in genotypic risks. Ann. Neurol., 37 (1995) 254-259.
40. [40] W.J. Strittmater et al., Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer's disease. Proc. Natl. Acad. Sci., 91 (1994) 11 183-11 186.
41. [41] T. Polikoski et al., Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N. Engl. J. Med., 333 (1995) 1242-1247.
42. [42] K. Okuizumi et al., Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat. Genet., 11 (1995) 207-209.
43. [43] G.W. Rebeck et al., Reduced apolipoprotein ∈4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology, 44 (1994) 1513-1516.
44. [44] R.E. Mrak, J.G. Shenh and W.S. Griffin, Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum. Pathol., 26 (1995) 816-823.
45. [45] A.D. Snow et al., Heparan sulfate proteoglycan in diffuse placques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am. J. Pathol., 144 (1994) 337-347.
46. [46] R. Gupta-Bansal, R.C. Frederickson, and K.R. Brunden, Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J. Biol. Chem., 270 (1995) 18666-18671.
47. [47] W. Samuel et al., Clinical correlates of cortical and nucleus basalis pathology in Alzheimer's dementia. Arch. Neurol., 51 (1994) 772-778.
48. [48] P. Seubert et al., Detection of phosphorylated ser-262 in fetal tau, adult tau, and paired helical filaments. J. Biol. Chem., 270 (1995) 18917-18922.
49. [49] H.K. Paudel, J. Lew, Z. Ali and J.H. Wang, Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem., 265 (1993) 23512-23518.
50. [50] C. Vigo-Pelfrey et al., Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology, 45 (1995) 788-793.
51. [51] R.E. Tato, A. Frank, and A. Hernanz, Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer's type, J. Neurol. Neurosurg. Psychiatry, 59 (1995) 280-283.
52. [52] H. Arai et al., Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann. Neurol., 38 (1995) 649-652.
53. [53] B.T. Hyman, T.E. Elvhage and J. Reiter, Extracellular signal regulated kinases: localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. Am. J. Pathol., 144 (1994) 565-572.
54. [54] I. Vincent, M. Rosado and P. Davies, Mitotic mechanisms in Alzheimer's disease? J. Cell. Biol., 132 (1996).
55. [55] A.D. Alonso, T. Zaidi, I. Grunde-Iqbal and K. Iqbal, Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer's disease. Proc. Natl. Acad. Sci., 91 (1994) 5562-5566.
56. [56] J.Q. Trojanowski and V.M. Lee, Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. FASEB J., 9 (1995) 1570-1576.
57. [57] E.S. Matsuo et al., Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron., 13 (1994) 989-1002.
58. [58] H.M. Wisniewski, Aluminium, tau protein, and Alzheimer's disease. Lancet, 344 (1994) 204-205.
59. [59] C.R. Harrington et al., Alzheimer's-disease-like changes in tau protein processing with aluminium accumulation in brains of renal dialysis patients. Lancet, 343 (1994) 993-997.
60. [60] R. Raghupathi et al., Regional induction of c-fos and heat shock protein-72 mRNA following fluid-percussion injury in the rat. J. Cereb. Blood Flow Metab., 15 (1995) 467-473.
61. [61] M.S. Pollanen, P. Markiewicz, C. Bergeron and M.C. Goh, Twisted ribbon structure of paired helical filaments revealed by atomic force microscopy. Am. J. Pathol., 144 (1994) 869-873.
62. [62] O. Schweers, E.M. Mandelkow, and E. Mandelkow, Oxidation of cystein-322 in the repeat domain of microtubule-associated protein τ controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci., 92 (1995) 8463-8467.
63. [63] N. Maltby et al., Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: a double blind trial. BMJ, 308 (1994) 879-883.
64. [64] E.J. Mufson and J.H. Kordower, Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer's disease. Proc. Natl. Acad. Sci., 89 (1992) 569-573.
65. [65] S. Rabizadeh, C.M. Bitler, L.L. Butcher, and D.E. Bredesen, Expression of low-affinity nerve growth factor enhances β-amyloid peptide toxicity. Proc. Natl. Acad. Sci., 91 (1994) 10703-10706.
66. [66] B.A. Yankner, A. Caceres, L.K. Duffy, Nerve growth factor potentiates the neurotoxicity of beta amyloid. Proc. Natl. Acad. Sci., 87 (1990) 9020-9023.
67. [67] M.H. Tuszynski, U.H. Sang, K. Yoshida and F.H. Gage, Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol., 30 (1991) 625-636.
68. [68] C. Flicker, S.H. Ferris, D. Kalkstein, and M. Serby, A double-blind placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease. Am. J. Psychiatry, 151 (1994) 126-129.
69. [69] D.P. Behan et al., Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature, 378 (1995) 284-287.
70. [70] J. Vaughan, C. Donaldson, J. Bittencourt et al., Urocortin, a mammalian neuropeptide related to fish urotensin 1 and to corticotropin-releasing factor. Nature, 378 (1995) 287-292.
71. [71] P. Jenner, Oxidative damage in neurodegenerative disease. Lancet, 344 (1994) 769-772.
72. 2+ homeostasis and cell death. J. Neurosci., 15 (1995) 6239-6249.
73. [73] M.E. Boerrigter, J.Y. Wei and J. Vijg, DNA repair and Alzheimer's disease. J. Gerontol., 47 (1992) 13177-13184.
74. [74] M.A. Smith et al., Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol., 145 (1994) 42-47.
75. [75] K.I. Saito, J.S. Elce, J.E. Hamos and R.A. Nixon, Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer's disease: A potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci., 90 (1993) 2628-2632.
76. [76] M. Didier et al., DNA strand breaks induced by sustained glutamate excitotoxicity in primary neuronal cultures. J. Neurosci., 16 (1996) 2238-2250.
77. [77] M. P. Mattson, M.A. Lovell, W.D. Ehmann and W.R. Markesbery, Comparison of the effects of elevated intracellular aluminum and calcium levels on neuronal survival and tau immunoreactivity. Brain Res., 602 (1993) 21-31.
78. [78] J.T. Coyle and P. Puttfarcken, Oxidative stress and neurodegenerative disorders. Science, 262 (1993) 689-695.
79. [79] L.S. Schneider and P.N. Tariot, Emerging drugs in Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med. Clin. N. Am., 78 (1994) 911-934.
80. [80] C.B. Thompson, Apoptosis in the pathogenesis and treatment of disease. Science, 267 (1995) 1456-1444.
81. [81] L.M. Kow and D.W. Pfaff, Estrogen effects on neuronal responsiveness to electrical and neurotransmitter stimulation: an in vitro study on the ventromedial nucleus of the hypothalamus. Brain Res., 347 (1985) 1-10.